Lipase Thera-blend for Forgetfulness

Overseen By David Crowley, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Enzymedica

Must not be taking: Cannabinoids, Insulin

Disqualifiers: Pregnancy, Neuropsychological conditions, Diabetes, others

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

90 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines whether Lipase Thera-blend, a dietary supplement, alone or with tributyrin, can improve memory in healthy adults experiencing forgetfulness. Participants will take either the supplement or a placebo and complete memory questionnaires to assess any improvement. The study seeks individuals with self-reported memory issues but without dementia or significant cognitive impairments. As an unphased trial, it offers participants the chance to contribute to early-stage research that could provide new insights into memory improvement.

Do I need to stop taking my current medications to join the trial?

The trial requires participants to maintain their current lifestyle habits, including medications, as much as possible throughout the study. However, if you are using prescribed or over-the-counter medications that might impact the study's safety or effectiveness, you may need to stop or adjust them. It's best to discuss your specific medications with the study team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that Lipase Thera-blend and Lipase Thera-blend + tributyrin might be safe for people. Studies with similar ingredients have not reported any major safety issues. Lipase Thera-blend contains enzymes from a type of yeast and has been shown to help balance gut bacteria, suggesting it is well-tolerated and not harmful.

Tributyrin, a component of Lipase Thera-blend + tributyrin, has been studied for its effects on memory in mice. This research found it might help prevent memory loss, with no serious side effects reported. These findings suggest that both treatments could be safe, but more research is needed to confirm this in humans. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Lipase Thera-blend and its combination with tributyrin for forgetfulness because they offer a fresh approach compared to existing treatments for memory issues, which often include medications like cholinesterase inhibitors. Unlike these traditional options, Lipase Thera-blend utilizes enzymes from Candida rugosa and Rhizopus oryzae, introducing a novel mechanism of action. The combination with tributyrin adds an extra layer of uniqueness, potentially enhancing the benefits through a synergistic effect. This innovative approach has the potential to target forgetfulness differently, promising a new avenue for improving memory.

What evidence suggests that this trial's treatments could be effective for memory improvement?

Research has shown that Lipase Thera-blend, one of the treatments in this trial, might aid memory by improving digestion and balancing gut bacteria. One study found that lipase from Candida rugosa, a component of Lipase Thera-blend, can enhance gut health, which is associated with improved brain health. This suggests that Lipase Thera-blend might help improve memory in adults experiencing forgetfulness.

Another treatment arm in this trial combines Lipase Thera-blend with tributyrin. Early findings suggest that this combination might enhance these benefits further. Tributyrin supports gut health and has been linked to improved brain function. Together, they could potentially boost memory by creating a healthier gut environment, which might support better thinking and memory. ^{1 2 3 6 7}

Who Is on the Research Team?

David Crowley, MD

Principal Investigator

KGK Science Inc.

Are You a Good Fit for This Trial?

This trial is for healthy adults who feel they have memory problems. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.

Inclusion Criteria

I am between 30 and 79 years old.

Agrees to avoid first generation anti-allergy medication for 48 hours prior to in-clinic visits

Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits

Exclusion Criteria

Unstable metabolic disease or chronic diseases as assessed by the QI

Individuals who are pregnant, breast feeding, or planning to become pregnant during the study

Alcohol intake average of >2 standard drinks per day as assessed by the QI

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants consume either placebo, Lipase Thera-blend, or Lipase Thera-blend + tributyrin and complete memory questionnaires to assess memory

12 weeks

Regular visits for assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Lipase Thera-blend
• Lipase Thera-blend + Tributyrin

Trial Overview The study tests if Lipase Thera-blend alone or combined with tributyrin can improve memory in adults with self-reported forgetfulness. It compares these two treatments against a placebo through participant questionnaires.

How Is the Trial Designed?

Group I: Lipase Thera-blend + tributyrin Experimental Treatment 1 Intervention

Lipase Thera-blend + tributyrin consists of tributyrin and lipase from Candida rugosa and lipase from Rhizopus oryzae.

Group II: Lipase Thera-blend Experimental Treatment 1 Intervention

Lipase Thera-blend consists of lipase from Candida rugosa and lipase from Rhizopus oryzae

Group III: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Enzymedica

Lead Sponsor

KGK Science Inc.

Industry Sponsor

Trials

82

Recruited

6,400+

Najla Guthrie

KGK Science Inc.

Chief Executive Officer since 1997

Research career at the Centre for Human Nutrition, University of Western Ontario

Dr. Bibiane Zakaria

KGK Science Inc.

Chief Medical Officer since 2023

MD from an unspecified institution

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT07020494?term=lipase&viewType=Table&rank=1&checkSpell=

A Clinical Trial Investigating the Efficacy and Safety of ... The goal of this clinical trial is to investigate the efficacy and safety of Lipase Thera-blend and Lipase Thera-blend + tributyrin on memory in healthy ...

2. withpower.com withpower.com/trial/phase-self-reported-memory-problems-8-2025-959a0

Lipase Thera-blend for Forgetfulness Trial Overview The study tests if Lipase Thera-blend alone or combined with tributyrin can improve memory in adults with self-reported forgetfulness. It ...

3. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12271982/

Loss of lysosomal acid lipase contributes to Alzheimer's ... LAL gene therapy blunts Alzheimer' pathology, improving cognition and mood with age.

4. nature.com nature.com/articles/s41598-022-08840-7

Exogenous lipase administration alters gut microbiota ... Candida rugosa lipase (CRL), which has been shown to enhance gut microbiome and metabolite composition, can rebalance the gut microbiome composition and reduce ...

5. kgkscience.com kgkscience.com/improving-memory-through-digestion/

Improving Memory through Digestion The objective of this study is to investigate the safety and efficacy of Lipase Thera ... memory in a of healthy adults with self-reported memory problems ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10357178/

The Effects of Medium Chain Triglyceride for Alzheimer's ... This review provides some evidence that treatment with MCT could improve general cognitive function in APOE ɛ4 (−) cognitive impaired patients.

7. mdpi.com mdpi.com/1422-0067/21/4/1505

Lipids and Alzheimer's Disease Of all the different species of FAs, most studies support that increased risks of AD and cognitive decline are correlated with higher saturated fatty acids ( ...